GLYX-13, a molecular cousin to ketamine, induces similar antidepressant results without the street drug side effects
Background
Major depression affects about 10 percent of the adult population and is the second leading cause of disability in U.S. adults, according to the World Health Organization. Despite the availability of several different classes of antidepressant drugs such as selective serotonin reuptake inhibitors (SSRIs), 30 to 40 percent of adults are unresponsive to these medications. Moreover, SSRIs typically take weeks to work, which increases the risk for suicide.
Enter NMDA (N-methyl-D-aspartate) receptor modulators. In the 1970s, researchers linked the receptors to learning and memory. Biotech and pharmaceutical companies in the 1980s attempted to apply chemical blockers to these receptors as a means to prevent stroke. But blocking these receptors led to the opposite effect—–the rise of cardiovascular disease. Research in the field dampened until a glutamate receptor antagonist already approved for anesthesia, and known on the streets as “Special K”, ketamine, made headlines in the early 2000s. Human clinical studies demonstrated that ketamine can ward off major and bipolar depressive symptoms within 2 hours of administration and last for several days. Ketamine is fraught with serious side effects including excessive sleepiness, hallucinations, and substance abuse behavior.
“Ketamine lit the field back up,“ said Joseph Moskal, Ph.D., a molecular neurobiologist at Northwestern University and senior study author. “Our drug, GLYX-13, is very different. It does not block the receptor ion channel, which may account for why it doesn’t have the same side effects.”
Moskal’s journey with GLYX-13 came about from his earlier days as a Senior Staff Fellow in NIMH’s Intramural Research Program. While at NIMH, he created specific molecules, monoclonal antibodies, to use as new probes to understand pathways of learning and memory. Some of the antibodies he created were for NMDA receptors. When he moved to Northwestern University, Moskal converted the antibodies to small protein molecules. Comprised of only four amino acids, GLYX-13 is one of these molecules.
Previous electrophysiological and conditioning studies had suggested that GLYX-13, unlike ketamine, enhanced memory and learning in rats, particularly in the brain’s memory hub or hippocampus. GLYX-13 also produced analgesic effects. Using several rat behavioral and molecular experiments, Moskal’s research team tested four compounds: GLYX-13, an inactive, “scrambled” version of GLYX-13 that had its amino acids rearranged, ketamine, and the SSRI fluoxetine.
Results of the Study
GLYX-13 and ketamine produced rapid acting (1 hour) and long-lasting (24 hour) antidepressant-like effects in the rats. Fluoxetine, an SSRI that typically takes from 2–4 weeks to show efficacy in humans, did not produce a rapid antidepressant effect in this study. As expected, the scrambled GLYX-13 showed no antidepressant-like effects at all. The researchers observed none of the aforementioned side effects of ketamine in the GLYX-13–treated rats.
Protein studies indicated an increase in the hippocampus of the NMDA receptor NR2B and a receptor for the chemical messenger glutamate called AMPA. Electrophysiology studies in this brain region showed that GLYX-13 and ketamine promoted long-lasting signal transmission in neurons, known as long-term potentiation/synaptic plasticity. This phenomenon is essential in learning and memory. The researchers propose how GLYX-13 works: GLYX-13 triggers NR2B receptor activation that leads to intracellular calcium influx and the expression of AMPA, which then is responsible for increased communication between neurons.
These results are consistent with data from a recent Phase 2 clinical trial, in which a single administration of GLYX-13 produced statistically significant reductions in depression scores in patients who had failed treatment with current antidepressants. The reductions were evident within 24 hours and persisted for an average of 7 days. After a single dose of GLYX-13, the drug’s antidepressant efficacy nearly doubled that seen with most conventional antidepressants after 4–6 weeks of dosing. GLYX-13 was well tolerated and it did not produce any of the schizophrenia-like effects associated with other NMDA receptor modulating agents.
The Latest Bing News on:
Major depression
- Neuronetics Boasts 12% Revenue Increase, Expands Depression Treatment Sectoron May 10, 2024 at 5:00 am
In a recent disclosure, Pennsylvania-based biotech firm Neuronetics (NASDAQ: STIM) announced its first-quarter financial performance for 2024, revealing a promising 12% increase in revenue compared to ...
- Immune Cells: A Hidden Trigger for Anxiety, Depression, and Alzheimer’s Diseaseon May 9, 2024 at 6:37 pm
Research indicates that regulatory T cells (Tregs) might stabilize mood and prevent depression, with their depletion linked to increased anxiety and cognitive issues in Alzheimer’s models. Regulatory ...
- CMU Health gets new depression treatmenton May 9, 2024 at 2:47 pm
CMU Health will add non-invasive Transcranial Magnetic Stimulation (TMS) to its psychiatry clinic, located at 3201 Hallmark Ct. Suite B in Saginaw, as another therapeutic option for individuals ...
- High Burden of Disease, Depressive Symptoms Found in Underrepresented Groups Living With HIVon May 9, 2024 at 5:44 am
A high burden of HIV could indicate other underlying factors, such as limited access to health care resources and a risk of major depressive disorder.
- Ketamine Noninferior to ECT for Outpatients With Major Depressionon May 7, 2024 at 9:00 pm
N EW YORK CITY -- Treatment with ketamine was noninferior to electroconvulsive therapy (ECT) for major depressive disorder, two meta-analyses showed, though it was inferior for patients hospitalized ...
- New guidelines for depression care emphasize patient-centred approachon May 7, 2024 at 5:00 pm
Psychiatrists and mental health professionals have a new standard for managing major depression, thanks to refreshed clinical guidelines. Psychiatrists and mental health professionals have a new ...
- Depression Newson May 6, 2024 at 4:59 pm
Apr. 8, 2024 — Coronary artery disease and major depression may be genetically linked via inflammatory pathways to an increased risk for cardiomyopathy, a degenerative heart muscle disease ...
- Noninvasive Brain Stimulation Shows Rapid Relief for Major Depressionon May 2, 2024 at 8:19 am
An RCT suggests transcranial alternating current stimulation may be an effective treatment for major depression, but outside experts say more study is needed to confirm its benefit.
- Magnus Medical launches Saint neuromod system for major depressive disorder treatmenton May 1, 2024 at 9:43 am
Magnus Medical announced the commercial launch of its Saint neuromodulation system for treatment-resistant major depressive disorder (MDD).
- Why Depression Can Make It Hard to Know You're Depressedon April 29, 2024 at 8:05 am
Depression often leads to an extremely negative view of oneself, and even to self-hatred. These feelings and beliefs can interfere with recognizing them as a symptom of depression because they seem so ...
The Latest Google Headlines on:
Major depression
[google_news title=”” keyword=”Major depression” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
The Latest Bing News on:
Fix the internet
- T-Mobile delays free internet loophole fix after running into a problemon May 9, 2024 at 1:40 pm
T-Mobile has reportedly delayed the roll out of address verification on gateways, as well as the launch of the new Away plan.
- State accepting challenges fix broadband mapping errorson May 7, 2024 at 8:02 pm
New Mexico has been allocated nearly $700 million to connect unconnected or poorly connected areas in the state to broadband, but to make sure the right households are reaping the benefits of that ...
- 5 Ways to Fix the GTA V “Rockstar Game Services are Unavailable” Error on Windows PCson May 7, 2024 at 5:53 am
Here, we look at how you can fix Grand Theft Auto V’s “Rockstar game services are unavailable” error on Windows 11/10 PCs. Are you another player who can’t play GTA V or GTA Online because of that ...
- 9 Fixes for the "No Internet Secured" Error on Windows 10on May 6, 2024 at 3:35 am
Running into the "No Internet, secured" message? Fix this common wireless error with these tips and get back online.
- Slow Wi-Fi in Your Apartment? Here's How to Fix Iton May 3, 2024 at 6:00 am
A laggy internet connection makes streaming, gaming and web surfing frustrating. Here are CNET’s tips for getting a stronger signal throughout your place. Trey Paul is a CNET senior editor ...
- Give small businesses the ‘right to repair’on May 2, 2024 at 7:00 am
Thankfully, bipartisan members of Congress have introduced a commonsense proposal that would benefit small businesses and consumers: the Right to Equitable and Professional Auto Industry Repair Act.
- 5 Ways to Fix the Failed-to-Connect-to-Server Minecraft Error on Windows PCson April 30, 2024 at 9:25 am
This troubleshooting guide provides some possible resolutions for fixing the Minecraft error message that says, “Failed to connect to the server.” Are you seeking a fix for that server connectivity ...
- Is your internet being throttled? How to test and fix your speedson April 30, 2024 at 7:24 am
Learn more about why internet providers throttle your internet speed, how to tell when it's happening and what to do to prevent it.
- How to Fix the "No Internet Secured" Error on Windowson April 26, 2024 at 8:00 am
The message "No Internet, Secured" usually appears when your connection is weak. You can reboot your router to refresh your network, which might also improve its speed. Alternatively, you can also ...
- PS5 won’t connect to the internet? Here’s how to fix iton April 25, 2024 at 5:00 pm
However, many have faced difficulties with connecting their PS5 consoles to the internet. Before you rush to the nearest Sony store, use the troubleshooting tricks below to fix internet issues on PS5.
The Latest Google Headlines on:
Fix the internet
[google_news title=”” keyword=”fix the internet” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]